REGISTER
Relma-cel, China’s First Million-Yuan CAR-T, Enters the National Reimbursement List
On November 14, 2026, Xinyu Huang, Director of the Department of Medical Services Management at the National Healthcare Security Administration (NHSA), announced that JW Therapeutics’ relma-cel injection (Carteyva), a CD19-targeted autologous CAR-T therapy, had been added to the 2026 National Reimbursement Drug List. It is the first CAR-T product priced at RMB 1 million or more to enter the basic catalogue, which takes effect on January 1, 2027.

Relma-cel injection (trade name: Carteyva), a CD19-targeted autologous CAR-T therapy developed by JW Therapeutics, was added to China’s 2026 National Reimbursement Drug List on November 14, 2026. The decision was announced by Xinyu Huang, Director of the Department of Medical Services Management at the National Healthcare Security Administration (NHSA), at the 2026 Innovative Drug High-Quality Development Conference. It is the first CAR-T product priced at RMB 1 million or more to enter the basic medical insurance catalogue; the new catalogue takes effect on January 1, 2027.

Feng Tian, chairman and chief executive officer of JW Therapeutics, said the reimbursement negotiators described the outcome as “a historic moment for Chinese lymphoma patients.”MedJ learned that following this negotiation, the price of relma-cel may fall below RMB 300,000; in some regions, patients who meet basic medical insurance and supplementary coverage conditions may see out-of-pocket costs fall below RMB 100,000.

“The moment we heard the reimbursement talks had succeeded, it went from out of reach to within reach, and suddenly there was coverage,” said Hongfei Gu, founder of Lymphoma Home.

Article Key Points

• First million-yuan CAR-T product enters China’s basic reimbursement list; effective January 1, 2027

• RELIANCE study in China: best ORR 77.6%, best CR 53.5% in evaluable r/r DLBCL patients

• 4-year follow-up: estimated OS 66.7% in 58 evaluable patients; 82.5% among complete responders

• Negotiated price may fall below RMB 300,000; regional out-of-pocket cost may fall below RMB 100,000

• Family case report: about RMB 350,000 out of pocket after insurance reimbursement and company assistance

First Million-Yuan CAR-T Enters the Basic Reimbursement List

Lymphoma is not a single disease. It refers to malignant neoplasms arising from lymphocytes, which may develop in lymph nodes and involve the gastrointestinal tract, bone marrow and other sites, and it is broadly divided into Hodgkin lymphoma and non-Hodgkin lymphoma, each of which contains multiple subtypes with different treatments and prognoses.

Diffuse large B-cell lymphoma (DLBCL) is a common form of non-Hodgkin lymphoma. First-line treatment usually relies on combination chemotherapy and other regimens, and some patients achieve long-lasting remission. Others respond poorly to treatment or relapse after remission.

After relapse or refractory disease, physicians select subsequent therapy according to lymphoma subtype, previous treatment and the patient’s condition, including further drug therapy. Eligible patients may also receive autologous hematopoietic stem cell transplantation or CAR-T therapy.

CAR-T is sometimes described as a “living drug.” Rather than killing tumour cells with a chemical agent, it harnesses the patient’s own immune cells. T cells are collected and sent to a manufacturing facility for gene modification so that they express a chimeric antigen receptor (CAR) on their surface; after culture, expansion and quality testing, the modified cells are reinfused, where they recognise and attack tumour cells carrying the target antigen.

Relma-cel is an autologous CAR-T product targeting CD19, an antigen expressed on the surface of many B-cell lymphoma cells, which gives the modified T cells a target.

The option matters most for patients with relapsed or refractory disease. In people whose disease has remained uncontrolled through multiple lines of therapy, each relapse can narrow the space left for subsequent treatment, and CAR-T adds an option for some of them.

In the RELIANCE study conducted in China, relma-cel showed a best objective response rate of 77.6% and a best complete response rate of 53.5% among patients with relapsed or refractory DLBCL who underwent efficacy evaluation. Objective response combines partial response, in which tumour shrinkage met the evaluation criteria, and complete response, in which tumour was no longer evident on imaging. In the study’s 4-year follow-up, estimated overall survival was 66.7% among the 58 patients evaluable for efficacy, and estimated 4-year overall survival was 82.5% among patients who achieved a complete response.

The therapy has brought hope, but the cost remains a barrier that many families struggle to clear. Autologous CAR-T has to be manufactured for each patient individually, and production and delivery are complex. Public reporting indicated that relma-cel entered the 2026 National Reimbursement Drug List negotiation at RMB 1.29 million per patient unit.

Before this decision, relma-cel had already been included in the 2025 Commercial Health Insurance Innovative Drug Catalogue, and some commercial medical insurance products and city-level inclusive insurance programmes (Huiminbao) also offered coverage. Some patients were able to reach treatment only by combining several payment routes.

This year, the catalogue adjustment opened a channel through which eligible products from the commercial insurance catalogue could apply for the basic medical insurance list. Relma-cel’s entry through negotiation has given more patients reason to expect a lighter burden.

On production costs, Feng Tian, chairman and chief executive officer of JW Therapeutics, said the lentiviral vector is one of the key raw materials for relma-cel injection, and that the company’s in-house development and production of lentiviral vectors may help lower key raw material costs and improve supply stability.

Some Patients Are Already Receiving the Therapy

Hongfei Gu, founder of Lymphoma Home, has worked closely with lymphoma patients and their families for years. He notes that when patients first hear about CAR-T, what comes to mind is often the price, and many do not even ask further about the eligibility criteria.

The family of Ms. Zhang also spent years running to secure treatment and funding for her mother. Her mother is now 78. She was diagnosed with lymphoma in 2022 and went into remission after six cycles of chemotherapy. In May 2025, the disease relapsed and involved the brain. Her physicians told the family that without treatment she might have six months to live.

The family chose to try CAR-T. In late 2025, the patient received relma-cel in the Department of Hematology at Shanghai Tongji Hospital. Physicians collected her T cells first; while the product was being manufactured, she received bridging therapy to control the tumour, after which the cells were reinfused and she was monitored in hospital.

Observation after reinfusion is critical. When CAR-T cells act in the body, they may trigger cytokine release syndrome, with fever, hypotension and, in severe cases, organ dysfunction. Neurotoxicity and infections also require close monitoring and prompt handling by the treating team.

Ms. Zhang said her mother has passed through the post-treatment adverse reaction period and was discharged at the end of January 2026. The patient can now get out of bed, walk and care for herself; residual brain lesions remain under follow-up.

Getting the drug for the family carried a substantial financial burden. According to Ms. Zhang, the special drug coverage of Shanghai’s Huiminbao programme reimbursed about RMB 500,000, and after company concessions were added, the family’s final out-of-pocket payment was about RMB 350,000.

Before relma-cel entered basic medical insurance, Huiminbao, commercial medical insurance and company concessions had already shared part of the cost for some families. Even so, the out-of-pocket amount carried by the Zhang family remained a significant expense.

With relma-cel now in the basic reimbursement list, more eligible patients are expected to gain coverage. For families weighing treatment opportunity against cost, this is welcome news.

Gu expects more patients to benefit. He also notes that treatment experience and disease progression differ across patients with relapsed or refractory lymphoma, and which patients can receive reimbursement will depend on the specific restrictions set out with the catalogue.

Can Hospitals Deliver CAR-T Now That Reimbursement Has Arrived?

The cost barrier may fall, but CAR-T still cannot be delivered without an experienced team.

Sanbin Wang, director of the Department of Hematology at the 920th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army, said CAR-T is not an injection that follows a purchase. Patient selection, cell collection, product transport and storage, pre-infusion preparation and post-infusion monitoring all require a specialised team.

Bridging therapy is a critical step. Manufacturing takes time after cells are collected, so for patients whose disease is progressing quickly, physicians may use other therapies to control the tumour during the wait, giving the patient a chance to reach the point of reinfusion.

Bridging regimens are individualised. Physicians choose according to tumour burden, previous treatment, organ function and the patient’s tolerance, creating the conditions for reinfusion.

Even with reimbursement in place, Wang said, CAR-T continues to place high demands on the capability and experience of a medical centre. “It is a very expensive treatment, and there will be requirements of that kind for qualifications. Not all tertiary hospitals will be able to do it.”

Ms. Zhang also advises families to choose hospitals with experience. Her mother’s course showed that reinfusion is only part of treatment; observation afterwards and the management of complications matter just as much.

Drug admission is supported by recent policy. A notice on further improving the safe and rational formulation and use of innovative drugs, published on November 10, states that second-tier-and-above medical institutions should improve their systems for bringing innovative drugs into hospitals and stock them according to business capability and treatment needs. Category 1 new drugs in the basic medical insurance catalogue and the commercial insurance innovative drug catalogue do not count against the “one product, two specifications” limit and are excluded from some of the public medical institution performance monitoring indicators listed in the document.

For cases in which catalogue innovative drugs are used appropriately but are not suited to payment under disease-based standards, the notice supports institutions in filing a “special case” application, which is reviewed before payment is made.

With reimbursement in place, patients’ financial pressure may ease; whether hospitals can stock the drug and deliver cell therapy will determine whether patients can be treated in time.

Wang said this reimbursement decision may also offer a reference for other autologous CAR-T products seeking access to the basic medical insurance list.

For patients and families still looking for treatment options, what they hope for is more choice when they need it.

0
0
Loading